CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
Targeting the immune-stimulatory receptor 4-1BB has only yielded modest benefit in cancer treatment. In this study, the authors show that CD73 expression on effector T cells sustained by TGF-β drives tumor resistance to anti-4-1BB therapy and therefore TGF- β blockade can be used to overcome such re...
Guardado en:
Autores principales: | Siqi Chen, Jie Fan, Minghui Zhang, Lei Qin, Donye Dominguez, Alan Long, Gaoxiang Wang, Renqiang Ma, Huabin Li, Yi Zhang, Deyu Fang, Jeffrey Sosman, Bin Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/235ff9bd6b974909b1dbb2d39fa66731 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells
por: Christopher J. Stairiker, et al.
Publicado: (2021) -
CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
por: Nataliia Petruk, et al.
Publicado: (2021) -
CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells
por: Yo-Ping Lai, et al.
Publicado: (2021) -
Species difference of CD137 ligand signaling in human and murine monocytes.
por: Qianqiao Tang, et al.
Publicado: (2011) -
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li SY, et al.
Publicado: (2013)